Medios Stock

Medios Equity

The The Equity of Medios (ILM1.DE) as of Aug 12, 2026 is 514.22 M EUR. In the previous year, The Equity was 510.19 M EUR — a change of 0.79% (higher).

Equity

514.22 MEUR

YoY

0.79%

Last updated:

In 2026, Medios's equity was 514.22 M EUR, a 0.79% increase from the 510.19 M EUR equity in the previous year.

Access this data via the Eulerpool API

Medios Stock analysis

What does Medios do? Medios AG is a leading company in the supply of high-quality specialty preparations to patients. The company was founded in Berlin in 2004 and has been listed on the Frankfurt Stock Exchange since 2018. Medios AG quickly achieved a strong position in the German healthcare market and currently employs approximately 300 employees at multiple locations in Germany. The business model of Medios AG is based on the production and distribution of high-quality specialty preparations. These are developed and produced in close collaboration with customers such as hospitals and outpatient clinics. Medios AG's products are typically used to treat rare and chronic diseases, such as immunological diseases, cancer, and metabolic disorders. Medios AG offers a wide range of products and services. The company is divided into three areas. The first area is Medios AG's core business, the distribution of specialty preparations. This area includes the development, production, and distribution of specialty preparations. The portfolio includes, for example, medications for pain and inflammation, as well as preparations for the treatment of Parkinson's and Alzheimer's diseases. Another important aspect in the field of specialty preparations is the supply of patients with parenteral nutrition solutions. These are used in both outpatient and inpatient settings to provide care for patients with severe diseases. The second area is supply services. Here, Medios offers a comprehensive range of services to support customers in hospital care and outpatient patient care. An important aspect of this area is the support of hospitals in dealing with delegations. For example, training is offered to educate hospital staff on the management of certain diseases. The third area is clinical study support. Medios AG offers services and products to support customers in clinical studies. The range includes criteria for patient-related logistics, the delivery of placebos and blinded medications, as well as specialty preparations and parenteral nutrition solutions. In each of these areas, Medios brings its high expertise and experience to develop the best possible solutions for customers and patients. Overall, Medios AG has established itself as an important partner for the German healthcare sector. The company pursues a clear strategy focused on the development and production of specialty preparations for the treatment of serious and rare diseases. The company places the highest value on the quality and safety of its products, as well as comprehensive consultation and customer care. Medios has a strong network of partners and suppliers in the healthcare industry and is a respected contact for customers and other market participants due to its experience and expertise. Medios is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Medios's Equity

Medios's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Medios's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Medios's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Medios's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Medios’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Medios stock

The Equity of Medios is 514.22 M EUR in 2026.

The Equity of Medios changed from 510.19 M EUR to 514.22 M EUR, representing a 0.79% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Medios since 2006 – with annual values, charts, and detailed analysis.

The Equity's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Medios historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Medios

All Key Metrics — Medios